A positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes. It is apart of a series of anti-inflammatory lipid mediators whose brief appearance generally signals the resolution of inflammation. Lipoxin A4 (LXA4) is a potent inhibitor of leukotriene (LT)-triggered polymorphonuclear neutrophil (PMN)-endothelial cell interaction and also blocks PMN migration stimulated by LTB4. At a concentration of 10-7 M, LXB4 inhibits PMN migration stimulated by LTB4 and inhibits LTB4-induced adhesion of PMNs with an IC50 value of ~3 X 10-10 M.
1 Serhan, C.N., Hamberg, M., Samuelsson, B., et al. On the stereochemistry and biosynthesis of lipoxin B. Proc Natl Acad Sci USA 83 1983-1987 (1986). 2 Serhan, C.N., Hamberg, M., Samuelsson, B. Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 81 5335-5339 (1984). 3 Papayianni, A., Serhan, C.N., Brady, H.R. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 156 2264-2272 (1996).
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.